Arax Advisory Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-284
| Closed | -$37.5K | – | 3219 |
|
|
2025
Q1 | $37.5K | Buy |
284
+143
| +101% | +$18.9K | ﹤0.01% | 1060 |
|
|
2024
Q4 | $11.8K | Buy |
141
+8
| +6% | +$668 | ﹤0.01% | 1431 |
|
|
2024
Q3 | $9.73K | Buy |
133
+36
| +37% | +$2.63K | ﹤0.01% | 1426 |
|
|
2024
Q2 | $6.64K | Buy |
97
+78
| +411% | +$5.34K | ﹤0.01% | 1461 |
|
|
2024
Q1 | $1.32K | Hold |
19
| – | – | ﹤0.01% | 1109 |
|
|
2023
Q4 | $1.36K | Hold |
19
| – | – | ﹤0.01% | 1074 |
|
|
2023
Q3 | $990 | Hold |
19
| – | – | ﹤0.01% | 1134 |
|
|
2023
Q2 | $1.2K | Hold |
19
| – | – | ﹤0.01% | 1083 |
|
|
2023
Q1 | $1.03K | Buy |
19
+3
| +19% | +$162 | ﹤0.01% | 1096 |
|
|
2022
Q4 | $847 | Hold |
16
| – | – | ﹤0.01% | 1110 |
|
|
2022
Q3 | $1K | Buy |
16
+3
| +23% | +$188 | ﹤0.01% | 1187 |
|
|
2022
Q2 | $1K | Hold |
13
| – | – | ﹤0.01% | 1140 |
|
|
2022
Q1 | $1K | Buy |
+13
| New | +$1K | ﹤0.01% | 1128 |
|